StockData
BioMarin Pharmaceutical Inc logo

BioMarin Pharmaceutical Inc (BMRN) stock

BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3093% above fair value
$61.43+2.92 (+4.99%)

Close on Nov 18, 2026Market cap $11.89BP/E 161.7Yield –

BioMarin Pharmaceutical operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

BioMarin Pharmaceutical's operating income for the twelve months ending Jun 30, 2026 was $149.26M, down 80.8% year over year. For fiscal 2025 it was $409.48M, down 15.4% from the year before. The highest annual figure on record is $484.21M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$409.48M-15.4%
FY2024Dec 31, 2024$484.21M+160.6%
FY2023Dec 31, 2023$185.77M+15.4%
FY2022Dec 31, 2022$160.97M–
FY2021Dec 31, 2021-$82.34M–
FY2020Dec 31, 2020-$43.44M–
FY2019Dec 31, 2019-$100.46M–
FY2018Dec 31, 2018-$123.52M–
FY2017Dec 31, 2017-$14.70M–
FY2016Dec 31, 2016-$803.43M–
FY2015Dec 31, 2015-$110.70M–
FY2014Dec 31, 2014-$92.89M–
FY2013Dec 31, 2013-$156.01M–
FY2012Dec 31, 2012-$110.22M–
FY2011Dec 31, 2011-$33.89M-6329.8%
FY2010Dec 31, 2010$544.00K-96.7%
FY2009Dec 31, 2009$16.43M-58.7%
FY2008Dec 31, 2008$39.76M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$110.92M-59.9%
Q1 FY2026Mar 31, 2026$129.64M-42.1%
Q4 FY2025Dec 31, 2025-$44.61M-127.6%
Q3 FY2025Sep 30, 2025-$46.69M-141.0%
Q2 FY2025Jun 30, 2025$276.89M+129.9%
Q1 FY2025Mar 31, 2025$223.89M+153.1%
Q4 FY2024Dec 31, 2024$161.41M+491.7%
Q3 FY2024Sep 30, 2024$113.89M+273.1%
Q2 FY2024Jun 30, 2024$120.45M+83.7%
Q1 FY2024Mar 31, 2024$88.46M+41.8%
Q4 FY2023Dec 31, 2023$27.28M–
Q3 FY2023Sep 30, 2023$30.53M–
Q2 FY2023Jun 30, 2023$65.57M+67.5%
Q1 FY2023Mar 31, 2023$62.40M-54.6%
Q4 FY2022Dec 31, 2022-$13.09M–
Q3 FY2022Sep 30, 2022-$2.42M–
Q2 FY2022Jun 30, 2022$39.15M+235.4%
Q1 FY2022Mar 31, 2022$137.33M+447.4%
Q4 FY2021Dec 31, 2021-$65.88M–
Q3 FY2021Sep 30, 2021-$53.22M–
Q2 FY2021Jun 30, 2021$11.67M–
Q1 FY2021Mar 31, 2021$25.09M-76.1%
Q4 FY2020Dec 31, 2020-$51.52M–
Q3 FY2020Sep 30, 2020-$55.94M-1495.0%
Q2 FY2020Jun 30, 2020-$40.95M–
Q1 FY2020Mar 31, 2020$104.96M–
Q4 FY2019Dec 31, 2019-$9.16M–
Q3 FY2019Sep 30, 2019$4.01M–
Q2 FY2019Jun 30, 2019-$41.35M–
Q1 FY2019Mar 31, 2019-$53.95M–
Q4 FY2018Dec 31, 2018-$38.15M-165.7%
Q3 FY2018Sep 30, 2018-$15.74M–
Q2 FY2018Jun 30, 2018-$25.26M–
Q1 FY2018Mar 31, 2018-$44.37M–
Q4 FY2017Dec 31, 2017$58.05M–
Q3 FY2017Sep 30, 2017-$13.73M–
Q2 FY2017Jun 30, 2017-$38.81M–
Q1 FY2017Mar 31, 2017-$20.21M–
Q4 FY2016Dec 31, 2016-$89.62M–
Q3 FY2016Sep 30, 2016-$60.09M–

More BioMarin Pharmaceutical figures

See a number that looks wrong?